Navigation Links
New approaches in treating complicated childhood polycystic kidney disease
Date:4/26/2013

A collaborative team of physician-scientists at the Medical College of Wisconsin (MCW) and Children's Hospital of Wisconsin Research Institute has developed a new evidence-based, clinical algorithm to help physicians treat complex patients with autosomal recessive polycystic kidney disease (ARPKD).

Their invited manuscript, written by Grzegorz Telega, M.D., associate professor of pediatrics (gastroenterology and hepatology) at MCW and program director of hepatology at Children's Hospital of Wisconsin; David Cronin, II, M.D., Ph.D., professor of surgery and member of the new Transplantation Institute; and Ellis D. Avner, M.D. professor of pediatrics (nephrology) and physiology at MCW, and director of the Multidisciplinary Childhood PKD Program (MCPP) at Children's Hospital of Wisconsin Research Institute, appears in the April 17 edition of Pediatric Transplantation http://onlinelibrary.wiley.com/doi/10.1111/petr.12076/full.

ARPKD is a rare genetic disorder that causes progressive disease of the kidneys and liver. Of the patients with ARPKD who survive the first year of life, more than 85 percent will reach their tenth birthday. However, despite dramatic improvements in overall survival and quality of life, nearly 50 percent of those survivors develop end stage kidney disease during that time.

Based on a comprehensive analysis of published medical literature, unique insights generated from the MCPP (established in 2005 and the only such program in the U.S.) and more than 50 years of clinical experience by the authors in treating complex problems in ARPKD patients, an algorithm was developed to guide patient therapy. Of particular note, the authors recommend an innovative approach for a subgroup of ARPKD patients with severe kidney and liver disease: simultaneous kidney and liver transplantation.

"We believe co
'/>"/>

Contact: Maureen Mack
mmack@mcw.edu
414-955-4744
Medical College of Wisconsin
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Daily-use HIV prevention approaches prove ineffective among women in NIH study
2. Common Sense Approaches May Stem ICU Delirium
3. Jan 31 W-2 1099 Form Mailing Deadline Approaches: EzW2 Software Helps Small Businesses Get Form Ready in Time
4. Cutting-edge approaches to ensuring biologic drug quality focus of forum on bioassays
5. As painkiller overdoses mount, researchers outline effective approaches to curb epidemic
6. NIH awards $7.8 million for innovative HIV vaccine approaches
7. GWU consensus report outlines new approaches for evaluating benefits and risks of obesity drugs
8. Scripps Florida scientists awarded nearly $1.5 million to develop new approaches to treat cancer
9. Treating Hemorrhoids
10. How “Hemorrhoids No More” Helps People Treat Hemorrhoids Quickly – V-kool
11. Treating Allergies with Traditional Medicine: Ayurvedic Medicine During the Spring Season 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... 28, 2015 Could genetic code determine ... study by researchers at the Harvard T.H. ... the support of the Coffee and Caffeine Genetics Consortium ... this past fall, the study—one of several recent HSPH ... data from more than 120,000 regular coffee drinkers of ...
(Date:3/28/2015)... 28, 2015 Take a bite of ... into action. Acids tumble into the stomach, ready to ... valve-like structure lets these acids run amok, triggering a ... common symptom. More than 60 million Americans have heartburn ... where heartburn starts, and how it can be stopped. ...
(Date:3/28/2015)... 28, 2015 Thousands of transvaginal ... by C.R. Bard, Inc. continue to move forward ... Court, Southern District of West Virginia, where Bernstein ... the Plaintiffs’ Steering Committee. According to an ... certain defendants named in those lawsuits leave to ...
(Date:3/28/2015)... 28, 2015 Emergency Medical Care (EMC), ... in Manhattan, recently commemorated its three-year anniversary of being ... In addition to 24-hour urgent care, Emergency Medical Care ... At this time, Emergency Medical Care’s Urgent Care ... chest pain, eye injuries, ear infections, fevers, insect bites, ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4
... Its Educational and Entertaining MusicMINNETONKA, Minn., May 6 ... activities for young children, today announced that its founder, ... The National Parenting Center for her new CD, "Dance ... "really impressed ... with its ability to entertain and ...
... SOUTH SAN FRANCISCO, Calif., May 6 Sunesis Pharmaceuticals, ... results for the first quarter ended March 31, 2009.Total ... million, with a net loss of $8.4 million, including ... 2009, cash, cash equivalents and marketable securities totaled $4.3 ...
... China, May 6 /PRNewswire-Asia/ -- China Medicine ... "the Company"), a developer,and a leading distributor ... Chinese medicines (TCM), nutritional and dietary supplements, ... that it will conduct,a conference call at ...
... NeoStem, Inc. (NYSE Amex: NBS ), ... storage of adult stem cells for future medical need, ... cell technology of Vincent C. Giampapa, M.D., F.A.C.S. ... in February 2009.The newest adult stem cell collection center ...
... ENMD ), a clinical-stage pharmaceutical company developing ... today reported financial results for the three months ended ... ) , The Company reported a net loss ... ($0.04) per share, compared with a net loss of ...
... Md., May 6 Micromet, Inc. (Nasdaq: ... for the treatment of cancer, inflammation and autoimmune diseases, ... ended March 31, 2009.In the first quarter of 2009, ... continued progress in the clinic and in corporate development. ...
Cached Medicine News:Health News:Tessa, of Dancercise Kids, Wins the National Parenting Center's Seal of Approval for New Children's Music CD 2Health News:Sunesis Reports Financial Results for the First Quarter 2009 2Health News:Sunesis Reports Financial Results for the First Quarter 2009 3Health News:Sunesis Reports Financial Results for the First Quarter 2009 4Health News:Sunesis Reports Financial Results for the First Quarter 2009 5Health News:Sunesis Reports Financial Results for the First Quarter 2009 6Health News:Sunesis Reports Financial Results for the First Quarter 2009 7Health News:Sunesis Reports Financial Results for the First Quarter 2009 8Health News:Sunesis Reports Financial Results for the First Quarter 2009 9Health News:China Medicine Announces Conference Call to Discuss First Quarter 2009 Results 2Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 2Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 3Health News:EntreMed Reports First Quarter 2009 Financial Results 2Health News:EntreMed Reports First Quarter 2009 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 9
(Date:3/27/2015)... , March 27, 2015 XRpro ... for drug discovery and development services which features ... the pharmaceutical industry, announced financial results for the ... Timothy C.  Tyson, Chairman of XRpro Sciences commented, ... successfully transition from development stage to commercial stage ...
(Date:3/27/2015)... March 27, 2015 According to ... (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, ... Indication (AF, VT, WPW) - Global Forecasts to 2019 ", ... to reach around ~$4.73 Billion by 2019 with a ... to 2019. Browse   90   ...
(Date:3/27/2015)... , March 27, 2015  RXi Pharmaceuticals ... MirImmune LLC, today announced that they have ... RXi,s novel and proprietary sd-rxRNA® technology for ... The collaboration has the potential to result ... cancer treatments that could be a significant ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... Calif., May 18, 2011 Bayer HealthCare Pharmaceuticals, ... ONXX ) today announced results from a Phase ... with locally advanced or metastatic breast cancer previously ... Nexavar was associated with statistically significant improvements in ...
... SEATTLE, May 18, 2011 Dendreon Corporation (Nasdaq: ... poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and ... upcoming American Society for Clinical Oncology annual meeting in Chicago, ... on Monday, June 6, 2011, from 8:00 a.m. to 12:00 ...
Cached Medicine Technology:Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 2Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 3Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 4Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 5Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 6Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 7Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 8Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 2Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 3Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 4
For the quantitative determination of calcium in serum. Endpoint Reaction Product measured at 570 nm Linearity: 20 mg/dl...
Alanine Aminotransferase (ALT) reagent is used for the quantitative determination of alanine aminotransferase (Glutamate pyruvate transaminase, SGPT) in human serum....
... Intended for the quantitative determination ... serum or plasma. Two vials, ... tablets must be purchased separately ... Kinetic reaction. Wavelength: 340 nm. ...
... quantitative determination of alanine aminotransferase ... Single vial, dry powder reagent. ... purchased separately for conformity to ... 340 nm. Linearity: 440 U/L ...
Medicine Products: